Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease A Scientific Statement for Health Professionals From the American Heart Association

被引:2475
作者
McCrindle, Brian W.
Rowley, Anne H.
Newburger, Jane W.
Burns, Jane C.
Bolger, Anne F.
Gewitz, Michael
Baker, Annette L.
Jackson, Mary Anne
Takahashi, Masato
Shah, Pinak B.
Kobayashi, Tohru
Wu, Mei-Hwan
Saji, Tsutomu T.
Pahl, Elfriede
机构
关键词
AHA Scientific Statements; aneurysm; arteritis; coronary vessels; immunoglobulins; intravenous; Kawasaki syndrome; thrombosis; vasculitis; CORONARY-ARTERY ANEURYSMS; STEROID PULSE THERAPY; INTRAVENOUS IMMUNOGLOBULIN TREATMENT; DOBUTAMINE STRESS ECHOCARDIOGRAPHY; C-REACTIVE PROTEIN; CILIATED BRONCHIAL EPITHELIUM; CYTOPLASMIC INCLUSION-BODIES; CLINICAL-PRACTICE GUIDELINES; CARDIOVASCULAR RISK-FACTORS; GAMMA-GLOBULIN TREATMENT;
D O I
10.1161/CIR.0000000000000484
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Kawasaki disease is an acute vasculitis of childhood that leads to coronary artery aneurysms in approximate to 25% of untreated cases. It has been reported worldwide and is the leading cause of acquired heart disease in children in developed countries. METHODS AND RESULTS: To revise the previous American Heart Association guidelines, a multidisciplinary writing group of experts was convened to review and appraise available evidence and practice-based opinion, as well as to provide updated recommendations for diagnosis, treatment of the acute illness, and long-term management. Although the cause remains unknown, discussion sections highlight new insights into the epidemiology, genetics, pathogenesis, pathology, natural history, and long-term outcomes. Prompt diagnosis is essential, and an updated algorithm defines supplemental information to be used to assist the diagnosis when classic clinical criteria are incomplete. Although intravenous immune globulin is the mainstay of initial treatment, the role for additional primary therapy in selected patients is discussed. Approximately 10% to 20% of patients do not respond to initial intravenous immune globulin, and recommendations for additional therapies are provided. Careful initial management of evolving coronary artery abnormalities is essential, necessitating an increased frequency of assessments and escalation of thromboprophylaxis. Risk stratification for long-term management is based primarily on maximal coronary artery luminal dimensions, normalized as Z scores, and is calibrated to both past and current involvement. Patients with aneurysms require life-long and uninterrupted cardiology follow-up. CONCLUSIONS: These recommendations provide updated and best evidence-based guidance to healthcare providers who diagnose and manage Kawasaki disease, but clinical decision making should be individualized to specific patient circumstances.
引用
收藏
页码:E927 / E999
页数:73
相关论文
共 410 条
  • [1] Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient?
    Abolhassani, Hasssan
    Asgardoon, Mohammad Hossein
    Rezaei, Nima
    Hammarstrom, Lennart
    Aghamohammadi, Asghar
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (11) : 1229 - 1243
  • [2] Catheter interventional treatment in Kawasaki disease: a report from the Japanese Pediatric Interventional Cardiology Investigation Group
    Akagi, T
    Ogawa, S
    Ino, T
    Iwasa, M
    Echigo, S
    Kishida, K
    Baba, K
    Matsushima, M
    Hamaoka, K
    Tomita, H
    Ishii, M
    Kato, H
    [J]. JOURNAL OF PEDIATRICS, 2000, 137 (02) : 181 - 186
  • [3] OUTCOME OF CORONARY-ARTERY ANEURYSMS AFTER KAWASAKI-DISEASE
    AKAGI, T
    ROSE, V
    BENSON, LN
    NEWMAN, A
    FREEDOM, RM
    [J]. JOURNAL OF PEDIATRICS, 1992, 121 (05) : 689 - 694
  • [4] VALVULAR HEART-DISEASE IN KAWASAKI SYNDROME - INCIDENCE AND NATURAL-HISTORY
    AKAGI, T
    KATO, H
    INOUE, O
    SATO, N
    IMAMURA, K
    [J]. AMERICAN HEART JOURNAL, 1990, 120 (02) : 366 - 372
  • [5] Kawasaki disease in Jordan: demographics, presentation, and outcome
    AL-Ammouri, Iyad
    Al-Wahsh, Shorouk
    Khuri-Bulos, Najwa
    [J]. CARDIOLOGY IN THE YOUNG, 2012, 22 (04) : 390 - 395
  • [6] Combination therapy with clopidogrel and aspirin - Can the CURE results be extrapolated to cerebrovascular patients?
    Albers, GW
    Amarenco, P
    [J]. STROKE, 2001, 32 (12) : 2948 - 2949
  • [7] Fibrinolytic response to venous occlusion is decreased in patients after Kawasaki disease
    Albisetti, M
    Chan, AKC
    McCrindle, BW
    Wong, D
    Vegh, P
    Adams, M
    Dinyari, M
    Monagle, P
    Andrew, M
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2003, 14 (02) : 181 - 186
  • [8] Kawasaki disease in Greek children: a retrospective study
    Alexopoulos, A.
    Vekiou, A.
    Lycopoulou, L.
    Tavena, A.
    Lagona, E.
    Kakourou, T.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (05) : 580 - 588
  • [9] MAXIMAL VOLUNTARY WORK AND CARDIORESPIRATORY FITNESS IN PATIENTS WHO HAVE HAD KAWASAKI SYNDROME
    ALLEN, SW
    SHAFFER, EM
    HARRIGAN, LA
    WOLFE, RR
    GLODE, MP
    WIGGINS, JW
    [J]. JOURNAL OF PEDIATRICS, 1992, 121 (02) : 221 - 225
  • [10] Alves NRD, 2011, REV ASSOC MED BRAS, V57, P295